BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 695K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

Advanced Search

26 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design.EBI
Amri
Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.EBI
Amri
The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties.EBI
Amri
The discovery of diazepinone-based 5-HT3 receptor partial agonists.EBI
Amri
Design, synthesis, and SAR of N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1.EBI
Amri
4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.EBI
Amri
Synthesis and SAR studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off-target kinase selectivity.EBI
Amri
Synthesis of 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-ylamine and its analogs as bombesin receptor subtype-3 agonists.EBI
Amri
5-Functionalized indazoles as glucocorticoid receptor agonists.EBI
Amri
Heterobiaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part II.EBI
Amri
Biaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part I.EBI
Amri
Epiminocyclohepta[b]indole analogs as 5-HT6 antagonists.EBI
Amri
Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.EBI
Amri
5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.EBI
Amri
Tetrahydrocarboline analogs as MCH-1 antagonists.EBI
Amri
Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.EBI
Amri
Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.EBI
Amri
Synthesis and SAR of heterocyclic carboxylic acid isosteres based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.EBI
Amri
2,3-Diaminopyrazines as rho kinase inhibitors.EBI
Amri
Synthesis and structure-activity relationship of substitutions at the C-1 position of Delta9-tetrahydrocannabinol.EBI
Amri
Application of combinatorial biocatalysis for a unique ring expansion of dihydroxymethylzearalenone.EBI
Amri
Synthesis and Biological Evaluation of N-((1-(4-(Sulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide Inhibitors of Glycine Transporter-1.EBI
Amri
Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1EBI
Amri
Bruton's Tyrosine Kinase Inhibitors for the Treatment of Autoimmune Diseases and Cancers.EBI
Amri
New Substituted Cyanoindoline Derivatives as MAP3K14 Kinase Inhibitors for the Treatment of Cancer and Autoimmune Disorders.EBI
Amri
Modulating GluN2B for the Treatment of Neurological and Psychiatric Disorders.EBI
Amri